Related Experiment Video

Updated: Mar 20, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K

Nintedanib in NSCLC: evidence to date and place in therapy

Giuseppe Bronte1, Francesco Passiglia1, Antonio Galvano1

  • 1Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Italy.

Therapeutic Advances in Medical Oncology
|May 31, 2016
PubMed

Insights

Nintedanib combined with docetaxel improves progression-free and overall survival in advanced non-small cell lung cancer (NSCLC) patients with adenocarcinoma. This combination offers a manageable safety profile for second-line treatment.

Area of Science:

  • Medical Oncology
  • Pharmacology

Background:

  • Advanced non-small cell lung cancer (NSCLC) treatment relies on identifying targetable oncogenic drivers.
  • Standard chemotherapy with bevacizumab is used for patients lacking known oncogenic drivers.
  • Second-line treatment options for NSCLC are crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of nintedanib plus docetaxel versus docetaxel alone in advanced NSCLC patients.
  • To assess nintedanib's role as a second-line treatment option.

Main Methods:

  • The LUME-Lung 1 trial investigated nintedanib plus docetaxel versus docetaxel alone.
  • Progression-free survival (PFS) and overall survival (OS) were primary endpoints.
  • Tolerability and safety profiles were also assessed.

Main Results:

  • The LUME-Lung 1 trial demonstrated significant improvements in PFS and OS for the nintedanib plus docetaxel arm.
  • Nintedanib, a tyrosine kinase inhibitor targeting angiogenesis-related receptors, showed efficacy in preclinical and early clinical trials.
  • The combination therapy exhibited a manageable tolerability profile.

Conclusions:

  • Nintedanib plus docetaxel is an effective second-line treatment for advanced NSCLC patients with adenocarcinoma.
  • The positive results from the LUME-Lung 1 trial support the use of nintedanib in clinical practice for this patient population.
Keywords:
FGFRNSCLCPDGFRVEGFRangiogenesisnintedanibtargeted therapy

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
537
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K